Why Dermatology Practices Miss Revenue That’s Already Theirs

Here is something I have noticed after sitting across from enough dermatology practice owners: the ones who feel most stuck are rarely the ones with the weakest clinical programs. They are often the best clinicians in their market. Full schedule, strong outcomes, loyal and efficient staff. And yet the revenue never quite reflects what they are building.

That gap is not a mystery, once you know where to look. It is almost always structural. And the data that reveals it is sitting inside the practice already—in the EMR, the booking system, the device logs—waiting for someone to ask the right questions of it.

The Lagging Indicator Problem

Ask any practice owner which numbers they track, and you will hear the same list every time. Monthly collections. New patient count. Appointment fill rate. Procedure volume. These are considered as management tools. They are not. They are accounting records.

Every one of those metrics tells you what already happened. The patient who stopped returning after their second visit—that churn occurred weeks ago, maybe months ago, without a single alert. The device that sat idle 3 days a week—that capacity loss compounds quietly, month after month, invisible on the collections report until the annual review.

The research reflects what I see in practice. Increasing patient retention by just 5% can improve practice profits anywhere from 25% to 95%, yet even top-performing aesthetic clinics average retention rates of only 60% to 70%.¹ That means up to 4 in 10 patients who visit never return. Most practices have no system for identifying which four—not because the data does not exist, but because nobody built a process to surface it early enough to act.

A Composite Case: The Hidden Revenue Floor

The following is based on patterns observed across multiple dermatology practices offering both medical and cosmetic services. No single practice is described here, but every number reflects dynamics I have encountered repeatedly.

A practice generating $624,000 annually had a full schedule and a good clinical reputation. Nothing about the surface metrics suggested a problem. A structured diagnostic audit found four structural gaps that the standard reporting had never flagged:

• Laser and radiofrequency devices generating revenue for just 22% of available hours — capital sitting largely idle
• A 28% 90-day churn rate, with no reactivation protocol in place for lapsed patients
• Virtually no treatment sequencing; first-time neurotoxin patients were not being offered follow-on services at any consistent rate
• Monthly recurring revenue of just $3,200 (6.2% of gross), meaning the practice restarted from near-zero revenue every single month

Six months of structural intervention—no new marketing spend, no new clinical hires—produced the outcomes above (See Table 1). The practice crossed $972,000 annualized without acquiring a single additional patient. The revenue was always there. It was leaking.

Three Leading Indicators Worth Measuring

Leading indicators do not describe what happened. They predict what is about to happen if nothing changes. In a dermatology practice with cosmetic services, 3 consistently surface the most useful intelligence (See Table 2).

The first is retention inflection points. Most practices do not lose patients dramatically. They lose them quietly, between appointments. My observation—consistent with research showing repeat patients spend up to 67% more than first-time visitors¹—is that the critical drop-off for cosmetic patients happens between visit 2 and visit 3. A patient who comes back a third time has crossed a loyalty threshold; one who does not has almost certainly gone somewhere else. Tracking that specific junction, broken down by provider and procedure type, turns a vague retention concern into something you can actually manage.

The second is procedure sequencing gaps. A first-time neurotoxin patient is a natural candidate for a collagen-stimulating treatment, a skin care consultation, a biostimulator conversation, or—increasingly—a GLP-1 adjunct discussion. That recommendation should happen every time, from every provider. In most practices, it does not, not because patients would refuse, but because the system for making the recommendation was never built. Clinics offering combination treatment pathways report up to 30% higher retention rates than those relying on single-service visits.² A weekly audit of recommendation rates by provider is often the fastest lever a practice can pull.

The third is idle capital asset utilization. Most dermatology practices have made significant investments in energy-based devices. When those devices generate revenue for less than half their available hours, the practice is carrying the full cost of ownership and capturing only a fraction of the potential. Checking utilization weekly rather than monthly creates a 4-week early warning window that the collections report cannot provide. The industry is on a trajectory toward $10 billion in revenue by 2025, with non-surgical cosmetic services as the fastest-growing segment.³ Practices that are not tracking device utilization as a leading indicator will find that growth accrues elsewhere.

The Diagnostic Shift

This does not require new technology. Appointment history, procedure records, provider schedules, device booking logs—all of it already exists in whatever practice management system is in use. The barrier is not access. It is framework. Knowing which data points matter, how they relate to each other, and what they predict requires a different kind of attention than what monthly collections reporting asks for.

When practices make this shift, what I hear consistently is not “we found a new problem.” It is “we finally have a name for something we always suspected was there.” The provider whose patients consistently do not rebook. The service that drives first visits but never second ones. The Tuesday afternoon that has been running at 40% capacity for 18 months.

Predictive diagnostics do not create new information. They surface the patterns already embedded in the data; early enough to intervene rather than simply document.

Looking Forward

The clinical side of dermatology has never been more sophisticated. The commercial side is catching up, but unevenly. Cosmetic and non-surgical services now account for 50% of dermatology industry revenue, and energy-based aesthetics alone is projected to grow from $1.5 billion in 2024 to $3.8 billion by 2033.⁴ The practices positioned to capture that growth are not necessarily those with the most advanced devices or the highest procedure volume.

They are the practices where ownership asks better questions of the data they already have.

The revenue is already there. The question is whether the practice is built to see it.

Harparam Sandhu, MD, is the founder of InnoHealth Studio and the creator of the MIAR framework, a diagnostic system for aesthetic and longevity practices. He is a contributor to MedEsthetics and has an upcoming column with Modern Aesthetics, publishing this summer.

References

1. ProspyrMed. 7 Retention Metrics for Aesthetic Clinics. ProspyrMed Blog. May 2025. https://www.prospyrmed.com/blog/post/7-retention-metrics-for-aesthetic-clinics

2. PharmiWeb. Global Medical Aesthetics Market: Trends, Growth & Future Outlook (2025–2030). PharmiWeb.com. July 2025. https://www.pharmiweb.com/press-release/2025-07-14/global-medical-aesthetics-market-trends-growth-future-outlook-2025-2030

3. IBISWorld. Dermatologists Industry in the United States. IBISWorld. 2025. https://www.ibisworld.com/united-states/industry/dermatologists/4168/

4. IAPAM. Top Aesthetic Medicine Trends to Watch in 2026. IAPAM. March 2026. https://iapam.com/2026-aesthetic-medicine-trends